G Guerbet
G
Suletud
8.07 -7.88
Ülevaade
Aktsiahinna muutus
24h
Min
8.06
Max
8.76
Sissetulek | -111M |
|---|---|
Müük | 399M |
P/E Sektori keskmine | 13.443 62.58 |
Kasumimarginaal | -27.836 |
Töötajad | 2,653 |
EBITDA | 14M |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | +22.77% upside |
Järgmine tulemuste avaldamine | 23. sept 2026 |
|---|
Turukapital | 110M |
|---|---|
Eelmine avamishind | 15.95 |
Eelmine sulgemishind | 8.07 |
Guerbet Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Guerbet Prognoos
Hinnasiht
By TipRanks
22.77% tõus
12 kuu keskmine prognoos
Keskmine 17.09 EUR 22.77%
Kõrge 17.093 EUR
Madal 17.093 EUR
Põhineb 1 Wall Streeti analüütiku instrumendi Guerbet 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Guerbet
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
